

# Vinod Chandran

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6365936/publications.pdf>

Version: 2024-02-01

180  
papers

9,585  
citations

36203

51  
h-index

45213

90  
g-index

232  
all docs

232  
docs citations

232  
times ranked

9274  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. <i>Nature Genetics</i> , 2012, 44, 1341-1348.	9.4	848
2	Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. <i>Journal of Autoimmunity</i> , 2010, 34, J314-J321.	3.0	403
3	Rare and Common Variants in CARD14, Encoding an Epidermal Regulator of NF-kappaB, in Psoriasis. <i>American Journal of Human Genetics</i> , 2012, 90, 796-808.	2.6	306
4	Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. <i>Nature Communications</i> , 2017, 8, 15382.	5.8	251
5	Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture. <i>American Journal of Human Genetics</i> , 2015, 97, 816-836.	2.6	245
6	Cardiovascular and other comorbidities in patients with psoriatic arthritis: A comparison with patients with psoriasis. <i>Arthritis Care and Research</i> , 2011, 63, 1729-1735.	1.5	214
7	The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 915-923.	2.9	197
8	Depression and Anxiety in Psoriatic Disease: Prevalence and Associated Factors. <i>Journal of Rheumatology</i> , 2014, 41, 887-896.	1.0	184
9	Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2152-2154.	0.5	183
10	Fine Mapping Major Histocompatibility Complex Associations in Psoriasis and Its Clinical Subtypes. <i>American Journal of Human Genetics</i> , 2014, 95, 162-172.	2.6	182
11	Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis. <i>Ophthalmology</i> , 2018, 125, 757-773.	2.5	178
12	Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. <i>Rheumatology</i> , 2012, 51, 571-576.	0.9	166
13	Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci. <i>Nature Communications</i> , 2015, 6, 7001.	5.8	156
14	Functional Assessment of Chronic Illness Therapy-Fatigue Scale is valid in patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 936-939.	0.5	153
15	Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. <i>Nature Reviews Rheumatology</i> , 2018, 14, 363-371.	3.5	149
16	Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. <i>Rheumatology</i> , 2010, 49, 1399-1405.	0.9	142
17	Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 813-817.	0.5	138
18	Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 50-55.	0.5	131

#	ARTICLE	IF	CITATIONS
19	Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2007, 57, 1560-1563.	6.7	129
20	Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program. <i>Rheumatology</i> , 2011, 50, 25-31.	0.9	115
21	Psoriatic arthritis. <i>Nature Reviews Disease Primers</i> , 2021, 7, 59.	18.1	113
22	Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. <i>Arthritis Care and Research</i> , 2011, 63, 1091-1097.	1.5	112
23	Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. <i>Arthritis Care and Research</i> , 2010, 62, 970-976.	1.5	110
24	Clinical Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort: Incidence, Prevalence, Characteristics, and Outcome. <i>Arthritis Care and Research</i> , 2017, 69, 1685-1691.	1.5	108
25	International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. <i>Arthritis and Rheumatism</i> , 2009, 61, 1235-1242.	6.7	104
26	Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1956-1961.	0.5	96
27	Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients. <i>Nature Communications</i> , 2018, 9, 4178.	5.8	95
28	Risk Factors for Axial Inflammatory Arthritis in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 809-815.	1.0	94
29	Axial Psoriatic Arthritis: Update on a Longterm Prospective Study. <i>Journal of Rheumatology</i> , 2009, 36, 2744-2750.	1.0	93
30	The Development of Psoriatic Arthritis in Patients With Psoriasis Is Preceded by a Period of Nonspecific Musculoskeletal Symptoms: A Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , 2017, 69, 622-629.	2.9	93
31	Gender difference in disease expression, radiographic damage and disability among patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 578-582.	0.5	88
32	Treatment Algorithms in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2015, 67, 1237-1245.	1.5	88
33	Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?. <i>Rheumatology</i> , 2020, 59, 1340-1346.	0.9	88
34	The Genetics of Psoriasis and Psoriatic Arthritis. <i>Clinical Reviews in Allergy and Immunology</i> , 2013, 44, 149-156.	2.9	86
35	Incidence and predictors for cardiovascular events in patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1680-1686.	0.5	85
36	The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1990-1996.	0.5	83

#	ARTICLE	IF	CITATIONS
37	Incidence of arthritis in a prospective cohort of psoriasis patients. <i>Arthritis Care and Research</i> , 2011, 63, 619-622.	1.5	81
38	Incremental Effects of Comorbidity on Quality of Life in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 1349-1356.	1.0	78
39	Is the Madrid Sonographic Enthesitis Index Useful for Differentiating Psoriatic Arthritis from Psoriasis Alone and Healthy Controls?. <i>Journal of Rheumatology</i> , 2014, 41, 466-472.	1.0	75
40	International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. <i>Journal of Rheumatology</i> , 2007, 34, 1740-5.	1.0	74
41	Dactylitis in Psoriatic Arthritis: Prevalence and Response to Therapy in the Biologic Era. <i>Journal of Rheumatology</i> , 2013, 40, 1357-1359.	1.0	72
42	Predictors of response to intra-articular steroid injection in psoriatic arthritis. <i>Rheumatology</i> , 2010, 49, 1367-1373.	0.9	70
43	The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 715-720.	0.5	70
44	Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1830-1835.	0.5	70
45	Brief Report: CXCL10 Is a Possible Biomarker for the Development of Psoriatic Arthritis Among Patients With Psoriasis. <i>Arthritis and Rheumatology</i> , 2016, 68, 2911-2916.	2.9	68
46	Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis?. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2160-2164.	0.5	66
47	Factors Explaining the Discrepancy Between Physician and Patient Global Assessment of Joint and Skin Disease Activity in Psoriatic Arthritis Patients. <i>Arthritis Care and Research</i> , 2015, 67, 264-272.	1.5	63
48	Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. <i>Journal of Rheumatology</i> , 2008, 35, 469-71.	1.0	62
49	Plasma Adipokine Levels and Their Association with Overall Burden of Painful Joints among Individuals with Hip and Knee Osteoarthritis. <i>Journal of Rheumatology</i> , 2014, 41, 334-337.	1.0	58
50	The association between sonographic enthesitis and radiographic damage in psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 189.	1.6	57
51	International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures. <i>Journal of Rheumatology</i> , 2007, 34, 1733-9.	1.0	57
52	Human leukocyte antigen alleles and susceptibility to psoriatic arthritis. <i>Human Immunology</i> , 2013, 74, 1333-1338.	1.2	51
53	Tumour necrosis factor $\hat{\pm}$ blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1007-1011.	0.5	50
54	Validation of the Toronto Psoriatic Arthritis Screen Version 2 (ToPAS 2). <i>Journal of Rheumatology</i> , 2015, 42, 841-846.	1.0	50

#	ARTICLE	IF	CITATIONS
55	Killer-cell immunoglobulin-like receptor gene polymorphisms and susceptibility to psoriatic arthritis. <i>Rheumatology</i> , 2014, 53, 233-239.	0.9	49
56	Identification of psoriatic arthritis mediators in synovial fluid by quantitative mass spectrometry. <i>Clinical Proteomics</i> , 2014, 11, 27.	1.1	49
57	Soluble Biomarkers Associated with Response to Treatment with Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 866-871.	1.0	48
58	Differentiating Psoriatic Arthritis From Psoriasis Without Psoriatic Arthritis Using Novel Serum Biomarkers. <i>Arthritis Care and Research</i> , 2018, 70, 454-461.	1.5	46
59	Folate Pathway Enzyme Gene Polymorphisms and the Efficacy and Toxicity of Methotrexate in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 1508-1512.	1.0	45
60	Minimal Disease Activity and Anti-“Tumor Necrosis Factor Therapy in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2015, 67, 842-847.	1.5	45
61	Proteinases and their receptors in inflammatory arthritis: an overview. <i>Nature Reviews Rheumatology</i> , 2018, 14, 170-180.	3.5	45
62	Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study. <i>Journal of Rheumatology</i> , 2018, 45, 378-384.	1.0	45
63	Quantitative tandem mass-spectrometry of skin tissue reveals putative psoriatic arthritis biomarkers. <i>Clinical Proteomics</i> , 2015, 12, 1.	1.1	44
64	The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA“B27 Status?. <i>Arthritis Care and Research</i> , 2021, 73, 856-860.	1.5	43
65	Inflammation in an individual joint predicts damage to that joint in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 305-308.	0.5	42
66	2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part II: Specific Management Recommendations. <i>Journal of Rheumatology</i> , 2015, 42, 665-681.	1.0	42
67	Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling. <i>Human Molecular Genetics</i> , 2017, 26, 4301-4313.	1.4	41
68	2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part I: Principles of the Management of Spondyloarthritis in Canada. <i>Journal of Rheumatology</i> , 2015, 42, 654-664.	1.0	39
69	The Risk of Developing Diabetes Mellitus in Patients with Psoriatic Arthritis: A Cohort Study. <i>Journal of Rheumatology</i> , 2017, 44, 286-291.	1.0	39
70	The Association Between Obesity and Clinical Features of Psoriatic Arthritis: A Case-control Study. <i>Journal of Rheumatology</i> , 2017, 44, 437-443.	1.0	39
71	Sleep Disturbance in Psoriatic Disease: Prevalence and Associated Factors. <i>Journal of Rheumatology</i> , 2017, 44, 1369-1374.	1.0	39
72	What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis?. <i>Current Opinion in Rheumatology</i> , 2015, 27, 91-98.	2.0	38

#	ARTICLE	IF	CITATIONS
73	pathDIP 4: an extended pathway annotations and enrichment analysis resource for human, model organisms and domesticated species. <i>Nucleic Acids Research</i> , 2020, 48, D479-D488.	6.5	38
74	Psoriatic arthritis disease activity during pregnancy and the first-year postpartum. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 740-745.	1.6	37
75	Gene Expression Differences between Psoriasis Patients with and without Inflammatory Arthritis. <i>Journal of Investigative Dermatology</i> , 2015, 135, 620-623.	0.3	36
76	Back pain in psoriatic arthritis: defining prevalence, characteristics and performance of inflammatory back pain criteria in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1573-1577.	0.5	36
77	Update on Biomarkers in Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2010, 12, 288-294.	2.1	35
78	Serum-based soluble markers differentiate psoriatic arthritis from osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 796-801.	0.5	34
79	Challenges in the clinical diagnosis of psoriatic arthritis. <i>Clinical Immunology</i> , 2020, 214, 108390.	1.4	33
80	Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 317-325.	1.4	32
81	Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases. <i>JCI Insight</i> , 2022, 7, .	2.3	32
82	Diffuse Idiopathic Skeletal Hyperostosis in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 1367-1373.	1.0	31
83	Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1). <i>Rheumatology</i> , 2020, 59, 2774-2784.	0.9	31
84	The Incidence and Predictors of Infection in Psoriasis and Psoriatic Arthritis: Results from Longitudinal Observational Cohorts. <i>Journal of Rheumatology</i> , 2016, 43, 362-366.	1.0	30
85	Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110579.	1.2	30
86	Patient-reported Outcome in Psoriatic Arthritis: A Comparison of Web-based Versus Paper-completed Questionnaires. <i>Journal of Rheumatology</i> , 2011, 38, 2619-2624.	1.0	29
87	Soluble Biomarkers May Differentiate Psoriasis from Psoriatic Arthritis. <i>Journal of rheumatology Supplement, The</i> , 2012, 89, 65-66.	2.2	29
88	Characteristic and Outcome of Psoriatic Arthritis Patients with Hyperuricemia. <i>Journal of Rheumatology</i> , 2018, 45, 213-217.	1.0	26
89	Psoriatic spondylitis or ankylosing spondylitis with psoriasis: same or different?. <i>Current Opinion in Rheumatology</i> , 2019, 31, 329-334.	2.0	26
90	Synovial fluid proteomics in the pursuit of arthritis mediators: An evolving field of novel biomarker discovery. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2017, 54, 495-505.	2.7	26

#	ARTICLE	IF	CITATIONS
91	Reliability of Radiographic Scoring Methods in Axial Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 1417-1422.	1.5	25
92	Fine mapping of eight psoriasis susceptibility loci. <i>European Journal of Human Genetics</i> , 2015, 23, 844-853.	1.4	25
93	Depression in Psoriatic Arthritis: Dimensional Aspects and Link with Systemic Inflammation. <i>Rheumatology and Therapy</i> , 2020, 7, 287-300.	1.1	25
94	Epigenome-wide analysis of sperm cells identifies IL22 as a possible germ line risk locus for psoriatic arthritis. <i>PLoS ONE</i> , 2019, 14, e0212043.	1.1	23
95	Mortality in psoriatic arthritis: Risk, causes of death, predictors for death. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 571-575.	1.6	23
96	Complexities in Genetics of Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2020, 22, 10.	2.1	23
97	Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study. <i>Nature Reviews Rheumatology</i> , 2021, 17, 238-243.	3.5	23
98	Toronto Psoriatic Arthritis Screening (ToPAS) Questionnaire: A Report from the GRAPPA 2009 Annual Meeting. <i>Journal of Rheumatology</i> , 2011, 38, 546-547.	1.0	22
99	Psoriatic Arthritis Mutilans: Clinical and Radiographic Criteria. A Systematic Review. <i>Journal of Rheumatology</i> , 2015, 42, 1432-1438.	1.0	22
100	Value of Carotid Ultrasound in Cardiovascular Risk Stratification in Patients With Psoriatic Disease. <i>Arthritis and Rheumatology</i> , 2019, 71, 1651-1659.	2.9	22
101	Depression and Anxiety Reduce the Probability of Achieving a State of Sustained Minimal Disease Activity in Patients With Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2022, 74, 1430-1434.	1.5	22
102	Biomarkers in Psoriatic Arthritis: Recent Progress. <i>Current Rheumatology Reports</i> , 2014, 16, 453.	2.1	21
103	Outcome of pregnancy in women with psoriatic arthritis compared to healthy controls. <i>Clinical Rheumatology</i> , 2019, 38, 895-902.	1.0	21
104	Role of Methotrexate in the Management of Psoriatic Arthritis. <i>Drugs</i> , 2018, 78, 611-619.	4.9	20
105	Quantifying Differences in Heritability among Psoriatic Arthritis (PsA), Cutaneous Psoriasis (PsC) and Psoriasis vulgaris (PsV). <i>Scientific Reports</i> , 2020, 10, 4925.	1.6	20
106	Relationship between spinal mobility and radiographic damage in ankylosing spondylitis and psoriatic spondylitis: a comparative analysis. <i>Journal of Rheumatology</i> , 2007, 34, 2463-5.	1.0	20
107	Delineating the synovial fluid proteome: Recent advancements and ongoing challenges in biomarker research. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2013, 50, 51-63.	2.7	19
108	What Is Axial Psoriatic Arthritis?. <i>Journal of Rheumatology</i> , 2018, 45, 1611-1613.	1.0	19

#	ARTICLE	IF	CITATIONS
109	Serum metabolic fingerprinting of psoriasis and psoriatic arthritis patients using solid-phase microextraction–liquid chromatography–high-resolution mass spectrometry. <i>Metabolomics</i> , 2021, 17, 59.	1.4	19
110	Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice. <i>Journal of Rheumatology</i> , 2017, 44, 519-534.	1.0	18
111	Association of variably expressed KIR3dl1 alleles with psoriatic disease. <i>Clinical Rheumatology</i> , 2017, 36, 2261-2266.	1.0	18
112	Exploring the Psoriatic Arthritis Proteome in Search of Novel Biomarkers. <i>Proteomes</i> , 2018, 6, 5.	1.7	18
113	The association between occupational-related mechanical stress and radiographic damage in psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 638-643.	1.6	18
114	Treating Psoriatic Arthritis to Target: Defining the Psoriatic Arthritis Disease Activity Score That Reflects a State of Minimal Disease Activity. <i>Journal of Rheumatology</i> , 2020, 47, 362-368.	1.0	18
115	Liver Abnormalities in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2020, 47, 847-853.	1.0	18
116	Connective Tissue Disorder-Associated Vasculitis. <i>Current Rheumatology Reports</i> , 2016, 18, 31.	2.1	17
117	Axial Disease in Psoriatic arthritis: The presence and progression of unilateral grade 2 sacroiliitis in a psoriatic arthritis cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 464-468.	1.6	17
118	Nonpharmacologic therapies in spondyloarthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2014, 28, 779-792.	1.4	16
119	Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 1718-1723.	1.0	16
120	Further Evidence Supporting a Parent-of-Origin Effect in Psoriatic Disease. <i>Arthritis Care and Research</i> , 2015, 67, 1586-1590.	1.5	15
121	Elucidating the endogenous synovial fluid proteome and peptidome of inflammatory arthritis using label-free mass spectrometry. <i>Clinical Proteomics</i> , 2019, 16, 23.	1.1	15
122	Sensitivity and Specificity of Radiographic Scoring Instruments for Detecting Change in Axial Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2017, 69, 1700-1705.	1.5	14
123	Magnetic Resonance Imaging in Psoriatic Arthritis. <i>Journal of Clinical Rheumatology</i> , 2017, 23, 243-245.	0.5	14
124	The Association Between HLA Genetic Susceptibility Markers and Sonographic Enthesitis in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 756-762.	2.9	14
125	Sex differences in the relationship between individual systemic markers of inflammation and pain in knee osteoarthritis. <i>Osteoarthritis and Cartilage Open</i> , 2019, 1, 100004.	0.9	14
126	Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa115.	1.4	14



#	ARTICLE	IF	CITATIONS
127	Genetics of psoriasis and psoriatic arthritis. Indian Journal of Dermatology, 2010, 55, 151.	0.1	14
128	Addressing comorbidities in psoriatic disease. Rheumatology International, 2018, 38, 219-227.	1.5	13
129	Patterns of peripheral joint involvement in psoriatic arthritisâ€”Symmetric, ray and/or row?. Seminars in Arthritis and Rheumatism, 2018, 48, 430-435.	1.6	13
130	The relationship between patient acceptable symptom state and disease activity in patients with psoriatic arthritis. Rheumatology, 2020, 59, 69-76.	0.9	13
131	Metabolomics Studies in Psoriatic Disease: A Review. Metabolites, 2021, 11, 375.	1.3	13
132	Novel Therapeutics in Psoriatic Arthritis. What Is in the Pipeline?. Current Rheumatology Reports, 2018, 20, 36.	2.1	12
133	Psoriatic Arthritis in Canadian Clinical Practice: The PsA Assessment in Rheumatology. Journal of Rheumatology, 2012, 39, 1850-1853.	1.0	11
134	The Association of HLA-class I Genes and the Extent of Atherosclerotic Plaques in Patients with Psoriatic Disease. Journal of Rheumatology, 2016, 43, 1844-1851.	1.0	11
135	Assessing disease activity in psoriasis and psoriatic arthritis: impact on management and therapy. Expert Review of Clinical Immunology, 2016, 12, 573-582.	1.3	11
136	Development of a Canadian Core Clinical Dataset to Support High-quality Care for Canadian Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2017, 44, 1813-1822.	1.0	11
137	Targeted metabolomic profiling and prediction of cardiovascular events: a prospective study of patients with psoriatic arthritis and psoriasis. Annals of the Rheumatic Diseases, 2021, 80, 1429-1435.	0.5	11
138	The incidence and risk factors for venous thromboembolic events in patients with psoriasis and psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2021, 51, 547-552.	1.6	11
139	Malignancy in psoriatic disease: Results from prospective longitudinal cohorts. Seminars in Arthritis and Rheumatism, 2021, 51, 144-149.	1.6	10
140	Using Acute-phase Reactants to Inform the Development of Instruments for the Updated Psoriatic Arthritis Core Outcome Measurement Set. Journal of Rheumatology, 2019, 46, 266-273.	1.0	9
141	International league of associations for rheumatology recommendations for the management of psoriatic arthritis in resource-poor settings. Clinical Rheumatology, 2020, 39, 1839-1850.	1.0	9
142	Incidence of and Risk Factors for Heart Failure in Patients With Psoriatic Disease: A Cohort Study. Arthritis Care and Research, 2022, 74, 1244-1253.	1.5	9
143	Insights into the pathogenesis of psoriatic arthritis from genetic studies. Seminars in Immunopathology, 2021, 43, 221-234.	2.8	9
144	Late onset psoriatic arthritis in a longitudinal cohort: Disease presentation, activity over time and prognosis. Seminars in Arthritis and Rheumatism, 2019, 48, 834-839.	1.6	8

#	ARTICLE	IF	CITATIONS
145	Proteinase-Mediated Macrophage Signaling in Psoriatic Arthritis. <i>Frontiers in Immunology</i> , 2020, 11, 629726.	2.2	8
146	Th17 gene expression in psoriatic arthritis synovial fluid and peripheral blood compared to osteoarthritis and cutaneous psoriasis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 486-489.	0.4	8
147	Investigational drugs for treating psoriatic arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1001-1016.	1.9	7
148	Clinical and Demographic Characteristics of Erosion-free and Erosion-present Status in Psoriatic Arthritis in a Cohort Study. <i>Journal of Rheumatology</i> , 2016, 43, 1057-1062.	1.0	7
149	Treatment of psoriatic arthritis with traditional DMARDs and novel therapies: approaches and recommendations. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 319-331.	1.3	7
150	Remission in psoriatic arthritis: Definition and predictors. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1494-1499.	1.6	7
151	Integrative Approach to Reveal Cell Type Specificity and Gene Candidates for Psoriatic Arthritis Outside the MHC. <i>Frontiers in Genetics</i> , 2019, 10, 304.	1.1	6
152	Development of a Modified Psoriatic Arthritis Disease Activity Score Using the Medical Outcomes Study Short Form 12 as a Measure of Quality of Life. <i>Arthritis Care and Research</i> , 2020, 72, 577-582.	1.5	6
153	GRAPPA 2013 Annual Meeting, Rheumatology Updates: Psoriatic Arthritis (PsA) Biomarker Project, Arthritis Mutilans, PsA-Peripheral Spondyloarthritis Epidemiology Project. <i>Journal of Rheumatology</i> , 2014, 41, 1244-1248.	1.0	5
154	A novel role for the psoriatic arthritis impact of disease (PsAID) questionnaire. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 241-245.	1.6	5
155	Prevalence and Factors Associated With Osteoporosis and Bone Mineral Density Testing in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2022, 74, 1006-1012.	1.5	5
156	Rho-GTPase pathways may differentiate treatment response to TNF-alpha and IL-17A inhibitors in psoriatic arthritis. <i>Scientific Reports</i> , 2020, 10, 21703.	1.6	5
157	Pathway to biomarker discovery in psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 471-478.	1.3	5
158	Oligoarticular vs Polyarticular Psoriatic Arthritis: A Longitudinal Study Showing Similar Characteristics. <i>Journal of Rheumatology</i> , 2021, 48, 1824-1829.	1.0	5
159	Association of Cardiac Biomarkers With Cardiovascular Outcomes in Patients With Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 1184-1192.	2.9	5
160	International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 684-685.	1.0	4
161	It Is High Time That We Define Axial Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2020, 47, 1301-1302.	1.0	4
162	Predicting therapeutic response through biomarker analysis in psoriatic arthritis, an example of precision medicine. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 35-42.	0.4	4

#	ARTICLE	IF	CITATIONS
163	Comparison Between INSPIRE and Domjan method for measuring lumbar lateral flexion in patients of psoriatic arthritis (PsA) and correlation with radiographic damage. <i>Clinical Rheumatology</i> , 2019, 38, 1063-1066.	1.0	3
164	Defining imaging sub-phenotypes of psoriatic arthritis: integrative analysis of imaging data and gene expression in a PsA patient cohort. <i>Rheumatology</i> , 2022, 61, 4952-4961.	0.9	3
165	Immunoglobulin G Subclass Analysis in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 2421-2424.	1.0	2
166	OUP accepted manuscript. <i>Journal of applied laboratory medicine</i> , The, 2022, 7, 281-293.	0.6	2
167	Psoriatic Arthritis: Current status. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101703.	1.4	2
168	Unusual Cause of Limited Elbow Movement in a Patient with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 2482-2483.	1.0	1
169	Pancytopenia in a Patient with Psoriatic Arthritis Treated with Methotrexate and Concomitant Lithium. <i>Journal of Rheumatology</i> , 2015, 42, 557-557.	1.0	1
170	Drs. Maharaj and Chandran reply. <i>Journal of Rheumatology</i> , 2015, 42, 1062-1062.	1.0	1
171	Reply. <i>Arthritis Care and Research</i> , 2016, 68, 1053-1054.	1.5	1
172	Response to: "Can biomarkers differentiate psoriatic arthritis from osteoarthritis?" by Tian <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e113-e113.	0.5	1
173	The association between synovial fluid serine proteinase activity and response to intra-articular corticosteroid injection in psoriatic arthritis. <i>Clinical Rheumatology</i> , 2020, 39, 2355-2361.	1.0	1
174	Psoriatic arthritis in developing and resource-poor countries. <i>Lancet Rheumatology</i> , The, 2020, 2, e200-e202.	2.2	1
175	Assessment of the Toronto Psoriatic Arthritis Screen 2 as a Screening Tool for Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2022, 26, 237-242.	0.6	1
176	Effectiveness of Disease Modifying Anti-Rheumatic Drugs for Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort. <i>Journal of Rheumatology</i> , 0, , jrheum.211231.	1.0	1
177	P261 Continuing versus withdrawing ixekizumab in patients with PsA who achieved sustained minimal disease activity: results from the SPIRIT-P3 study. <i>Rheumatology</i> , 2020, 59, .	0.9	0
178	The incidence and risk factors for venous thromboembolic events in patients with psoriasis and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 53, 151950.	1.6	0
179	GRAPPA 2020 Research Award Recipients. <i>Journal of Rheumatology</i> , 2022, , jrheum.211335.	1.0	0
180	Basic Science Session 1. Biomarkers for Psoriatic Arthritis Treatment Response and Joint Damage Progression: An Update on 2 Industry-GRAPPA Projects. <i>Journal of Rheumatology</i> , 2022, , jrheum.211320.	1.0	0